

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

Evaluating the feasibility of study methods for a future trial-based economic evaluation of a multistage shared decision-making program for type 2 diabetes mellitus: protocol for a cluster-randomized controlled pilot study

A. Tichler^{1*}, D.F.L. Hertroijs¹, G.A.P.G. van Mastrigt¹, M.C.G.J. Brouwers^{2,3}, D. Ruwaard¹, A.M.J. Elissen¹

¹Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Faculty of Health, Medicine and Life Sciences (FHML), Maastricht University, Maastricht, the Netherlands

²Care and Public Health Research Institute (CAPHRI), Faculty of Health, Medicine and Life Sciences (FHML), Maastricht University, Maastricht, the Netherlands

³Department of Internal Medicine, Division of Endocrinology and Metabolic Disease, Maastricht University Medical Center+, Maastricht, the Netherlands

*Corresponding author:
E-mail: a.tichler@maastrichtuniversity.nl (AT)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

28 **Abstract**

29 **Introduction**

30 We developed a multistage shared decision-making program for type 2 diabetes that aims to
31 support person-centered type 2 diabetes management in primary care. The program consists of an online
32 patient decision aid, a preparatory consult for patients, and interprofessional training for healthcare
33 professionals. The short- and long-term effectiveness of the multistage shared decision-making program
34 needs to be researched in a trial-based economic evaluation. To evaluate the feasibility of study methods
35 for future economic evaluation, we will conduct a pilot study that focuses on sample recruitment and
36 retention, study management, and feasibility of outcome and cost measurements.

37

38 **Methods and analysis**

39 The multistage shared decision-making program will be pilot-tested in a cluster-randomized
40 controlled trial in four primary care practices (located in the region of Gorinchem, the Netherlands)
41 using a mixed-methods approach. The intervention practices will adopt the program, whereas the control
42 practices provide usual care. Data collection will include recruitment, retention, and consent rates,
43 patients' sociodemographic and clinical characteristics, and the assessment of primary and secondary
44 outcomes of the future trial-based economic evaluation. We will also collect data on the usage behavior
45 of patients when completing questionnaires of the primary and secondary outcomes (i.e. time needed to
46 complete questionnaires). Semi-structured interviews with patients will be conducted to obtain insights
47 into the understandability and usability of measurement tools. Moreover, focus groups with healthcare
48 professionals from participating practices will be organized to complement the quantitative data on
49 sample representativeness and to assess the study management challenges of participating practices.

50

51 **Discussion**

52 The pilot will address uncertainties around the feasibility of a future trial-based economic
53 evaluation, focusing on sample recruitment and retention, study management, and the feasibility of
54 outcome and cost measurements. The results will guide the improvement of study procedures for the
55 economic evaluation of our multistage shared decision-making program for type 2 diabetes.

56

57 Introduction

58 Type 2 diabetes mellitus (T2DM) is associated with significant levels of morbidity and
59 mortality, reduced quality of life, and increased healthcare costs [1]. National and international clinical
60 guidelines for T2DM emphasize the need for person-centered care, including shared decision-making
61 (SDM), to decide on the best treatment course for an individual patient [2-4]. SDM is complex in T2DM
62 care due to the availability of many pharmacological and lifestyle treatment options. Patients and
63 healthcare professionals (HCPs) face difficult trade-offs in aligning treatment attributes (e.g. efficacy,
64 side effects) with patients' clinical factors and preferences. SDM support is needed to reap the full
65 benefits of person-centered T2DM care. We developed a multistage SDM program for T2DM that
66 combines (1) an online patient decision aid (PDA) with (2) a preparatory consult for patients, and (3)
67 interprofessional training in the PDA and SDM for HCPs [5]. The program was co-created with patients
68 with T2DM, healthcare professionals involved in T2DM care, and patient organizations.

69 Evidence shows that PDAs, in general, can reduce patients' decisional conflict, make them
70 better informed, more involved and satisfied with their treatment choices, and have a positive effect on
71 the communication between patients and HCPs [6]. There is some evidence suggesting that PDAs,
72 through their effective support of SDM, can lead to improvements in treatment adherence and
73 persistence, thereby resulting in better health outcomes and cost reduction [6]. However, the available
74 evidence for these effects remains limited [6]. Our multistage SDM program for T2DM is a complex
75 intervention as defined by the Medical Research Council (MRC) [7]. It consists of multiple, interacting
76 components, targets a diverse group of end-users, and influences a range of short- and long-term
77 outcome measures. A trial-based economic evaluation with the multistage SDM program needs to be
78 conducted to estimate short- and long-term effectiveness. It will strengthen the limited evidence about
79 the impact of person-centered care and SDM on mid and long-term outcomes such as treatment
80 adherence, health outcomes, and costs.

81 Previous randomized controlled trials researching the effects of SDM support through PDAs for
82 T2DM experienced several challenges related to study procedures (e.g. recruitment), resources (e.g.
83 time necessary to complete questionnaires), and study management (e.g. personnel and data

84 management for participating practices) [8-12]. These challenges include, for example, difficulties in
85 recruiting patients, understandability of questionnaires, timely recruitment, and inadvertent recruitment
86 bias. Recognizing the challenges faced in previous research, small-scale piloting is crucial to address
87 uncertainties around the feasibility of study methods and to improve the study procedures of an
88 economic evaluation [12, 13]. This article outlines the protocol for a cluster-randomized controlled pilot
89 study aimed at evaluating the feasibility of a future trial-based economic evaluation of a multistage SDM
90 program, including a PDA for T2DM in the Netherlands, compared to usual care [5]. The pilot study
91 specifically focuses on sample recruitment and retention, study management, and feasibility of outcome
92 and cost measurements. A mixed-methods approach will be used to identify and address potential
93 challenges for future trial-based economic evaluation.

94

95 **Research questions**

96 The pilot aims to address uncertainties around the feasibility of study methods. This includes the
97 need for strategies to deal with recruitment and retention challenges to ensure a study sample that
98 represents the diverse group of patients with T2DM for the intended economic evaluation [14].
99 Moreover, acknowledging the high workload and time constraints experienced by HCPs, we aim to gain
100 insights into how to minimize additional burdens on participating practices [15, 16]. Finally, considering
101 the complexity of the measurement process and the understandability of the measurement tools, the
102 outcomes and costs will be measured in the pilot study to refine study procedures for the intended
103 economic evaluation. Therefore, the research questions of this pilot study are:

- 104 1. What strategies can be employed to effectively recruit and retain a demographically and
105 clinically diverse sample of patients with T2DM?
- 106 2. How can we support primary care practices in effectively managing the challenges associated
107 with study participation?
- 108 3. How can we feasibly measure relevant SDM outcomes, treatment adherence, health outcomes,
109 and costs from a societal perspective for T2DM using valid and reliable measurement
110 instruments?

111 **Methods and analysis**

112 This protocol follows a combination of the Consolidated Standards of Reporting Trials
113 (CONSORT) extension to pilot trials [17] and the Standard Protocol Items: Recommendations for
114 Interventional Trials (SPIRIT) checklist for reporting protocol studies [18, 19], as described by Thabane
115 et al. [20] (S1-S2 File). For conducting and reporting the future economic evaluation, the Dutch
116 guidelines for economic evaluation [21] and the Consolidated Health Economic Evaluation Reporting
117 Standards 2022 (CHEERS 2022) Statement [22] will be followed, respectively. The pilot study starts
118 February 2024 and will last 15 months: 9 months for implementation (i.e. patient recruitment and data
119 collection) of the multistage SDM program, and 6 months for data analysis and reporting.

120

121 **Setting**

122 The majority of patients with T2DM in the Netherlands (90% in 2022) are treated in a primary care
123 setting organized by care groups [23]. Care groups are collaborations between healthcare professionals
124 (general practitioners and affiliated personnel) and are responsible for organizing, coordinating, and
125 providing care for patients with T2DM in their region [24]. A team comprising a general practitioner
126 and practice/diabetes nurse provides treatment following the national guidelines for T2DM of the NHG
127 [25]. Since most Dutch patients with T2DM are treated in primary care, the multistage SDM program
128 was developed based on the NHG guideline for T2DM and will be pilot-tested in a general practice
129 setting. Therefore, we collaborate with the primary care group ‘Huisarts & Zorg’, a group of 75 general
130 practices located in the region of Gorinchem (a municipality in South Holland) to recruit practices and
131 patients. Four primary care practices from the care group ‘Huisarts & Zorg’ will be included in this pilot
132 study.

133

134 **Study design**

135 The multistage SDM program will be piloted in a cluster-randomized controlled trial using a
136 mixed-methods approach to answer questions related to sample recruitment and retention, study

137 management, and feasibility of outcome and cost measurements. Randomization will be conducted by
138 cluster (i.e. primary care practices) to avoid possible contamination between the intervention and control
139 group [26]. Two primary care practices will be randomly assigned to the intervention group and two to
140 the control group. Simple randomization will be used to assign each primary care practice to a group
141 with an equal probability (1:1 allocation) using a computerized random number generator [27]. Both
142 patients with T2DM and HCPs are not blinded to the group assigned to them. Patients and HCPs from
143 the intervention practices will have access to the multistage SDM program. They will receive an account
144 to gain access to the PatientPlus platform, where the PDA is available. Patients and HCPs from the
145 control practices will provide and receive usual care according to the national guidelines for T2DM of
146 the Dutch College of General Practitioners (NHG) [25]. They will not have access to the multistage
147 program. Data will be collected from patients and healthcare professionals in both the intervention and
148 control practices.

149

150 **Participants**

151 To be able to recruit a diverse population of patients with T2DM, we aim to include general
152 practices from the care group ‘Huisarts & Zorg’ that differ in terms of the sociodemographic background
153 of their patient panels. HCPs from the participating practices will be asked to recruit patients who: 1)
154 are eighteen years or older; 2) need to decide on T2DM treatment based on the NHG guideline
155 (medication and/or lifestyle); and 3) speak Dutch at a necessary level to complete questionnaires and
156 ensure involvement in SDM. We will only exclude patients who have severe cognitive impairments that
157 hamper SDM. Patients will be enrolled in the study after receiving face-to-face and written information
158 about the research from their HCP and after giving written informed consent.

159

160 **Intervention**

161 The multistage SDM program combines an online PDA with a preparatory consultation for
162 patients as well as an interprofessional training in the PDA and SDM for HCPs (Fig 1). The program

163 was co-created with a multidisciplinary steering group representing all relevant stakeholders in Dutch
164 diabetes care. The development of the PDA for T2DM is described in detail elsewhere [5].

165

166 **Fig 1. Overview of the multistage shared decision-making program for type 2 diabetes mellitus.**

167 SDM: shared decision-making; PDA: patient decision aid; T2DM: Type 2 Diabetes Mellitus.

168

169 The PDA is available in the online catalog of PatientPlus ([https://www.keuzehulp.info/front-](https://www.keuzehulp.info/front-page/keuzehulpen/diabetes-type-2)
170 [page/keuzehulpen/diabetes-type-2](https://www.keuzehulp.info/front-page/keuzehulpen/diabetes-type-2), Dutch only), the largest supplier of PDAs in the Netherlands. In line
171 with the International Patient Decision Aids Standards (IPDAS) guidance, the PDA comprises five
172 sections: 1) information about T2DM and the available treatment options; 2) a comparison of treatment
173 options based on, for example, the risk of cardiovascular disease and effect on daily life; 3) questions to
174 assess patients' knowledge; 4) value-clarification exercise; and 5) summary of the patient's journey [28,
175 29].

176 To prepare and empower patients for SDM, our multistage program comprises a one-to-one
177 preparatory consultation with a trained facilitator. Each practice can decide whether a practice nurse,
178 medical assistant or other HCP will serve as a trained facilitator. The consultation will last 20-30 minutes
179 and is intended to help patients effectively use the PDA and provide them with the knowledge and
180 confidence needed to fully participate in SDM. The preparatory consultation takes place before the
181 clinical encounter where the treatment decision is made by a patient and HCP (i.e. a GP or specialized
182 nurse who can prescribe medication).

183 All participating HCPs (including the trained facilitators) from included intervention practices
184 receive a 2-hour interactive interprofessional training in SDM and the PDA, including communication
185 techniques and general instructions to increase SDM knowledge. HCPs will receive accreditation for
186 their participation in the training. The training is offered by PatientPlus. One intervision meeting
187 between the trained facilitators from all participating practices will be held to stimulate interprofessional
188 training.

189

190 **Sample size calculation**

191 The pilot study is a preparation for a large trial-based economic evaluation and therefore setting
192 the sample size for the pilot study in order to minimize the total sample size of the pilot study and main
193 trial together is the most suitable method of sample size calculation [30]. The sample size calculation
194 for the pilot study is based on a 90% powered main trial and an estimated medium (between 0.3 and 0.7)
195 effect size in the decisional conflict score (primary outcome of the intended economic evaluation) [31].
196 Using the stepped rules of thumb, the sample size for the pilot study would be 30 patients with T2DM
197 [30]. Due to possible loss to follow-up and drop-out, the sample size will be increased by a third. So,
198 the sample size for this pilot study will be set at 40 patients with T2DM, with 20 patients assigned to
199 each arm.

200

201 **Outcome measures**

202 The pilot study will focus on three aspects: 1) sample recruitment and retention; 2) study
203 management; and 3) feasibility of outcome and cost measurements. Each aspect has its own relevant
204 outcome measures and measurement instruments.

205

206 **Research question 1. Sample recruitment and retention**

207 To assess the extent to which a representative sample of T2DM patients is included and retained,
208 quantitative data will be collected on: (1) recruitment, retention and consent rates; (2) time required to
209 recruit the target sample size; and (3) sociodemographic and clinical characteristics. To interpret the
210 quantitative data and learn how to improve sample representativeness for the intended trial-based
211 economic evaluation, additional qualitative data will be collected through one-hour focus groups with
212 HCPs from the participating practices.

213

214 **Research question 2. Study management**

215 The focus groups with HCPs from participating practices will also be used to assess practices'
216 study management challenges. An interview guide, consisting of a set of semi-structured questions
217 related to study management (e.g. did the practice have the time to perform the tasks they committed to
218 doing? Did they experience any capacity issues?) will be used to guide the focus group.

219

220 **Research question 3. Feasibility of outcome and cost measurements**

221 We will assess the feasibility of primary and secondary outcome measurements of the intended
222 trial-based economic evaluation. The primary and secondary outcomes will solely be measured to assess
223 its measurement feasibility and not to determine the (cost-)effectiveness and cost-utility of the
224 multistage SDM program. The primary outcomes will focus on short-term SDM outcomes. Primary
225 outcomes include patient decisional conflict (using the 16-item Decisional Conflict Scale, DCS [32]),
226 level of SDM as perceived by patients (based on the 3-item CollaboRATE survey [33, 34] and SDM-
227 Q-9 questionnaire [35]), level of SDM as perceived by HCPs (using the SDM-Q-Doc questionnaire
228 [35]), and patient knowledge (with 9 tailor-made questions assessing patient's understanding of the
229 glucose-lowering treatments). The DCS, CollaboRATE, SDM-Q-9, and SDM-Q-Doc questionnaires
230 will be used for this pilot study due to their validity and wide applicability in assessing SDM in
231 healthcare. The long-term cost-effectiveness and cost-utility of our multistage SDM program will serve
232 as secondary outcomes in the intended trial-based economic evaluation. Assessing societal costs and
233 health-related quality of life is essential for conducting a cost-utility analysis since it allows us to
234 compare the multistage program with usual care by estimating how much it costs to reach improvements
235 in individuals' quality of life [36]. Moreover, in the future trial-based economic evaluation, we will also
236 conduct a cost-effectiveness analysis to estimate how much it costs to reach improvements in relevant
237 health outcomes (i.e. glycemic control). Therefore, secondary outcomes include glycemic control
238 (HbA1c obtained via the HCP), societal costs (measured with an adapted version of the iMTA
239 Productivity Costs Questionnaire (iPCQ) and iMTA Medical Consumption Questionnaire (iMCQ) [37,
240 38]), health-related quality of life (measured with the Dutch EuroQol (EQ) 5D-5L questionnaire

241 assessing quality of life [39]), and medication adherence (measured with the Medication Adherence
 242 Report Scale [40] and prescription data obtained via the pharmacist).

243 Table 1 provides an overview of the primary and secondary outcomes of the future trial-based
 244 economic evaluation, including their measurement tools. Semi-structured interviews with patients will
 245 be held to gain insight into the understandability and accessibility of the measurement tools. Interviews
 246 will be conducted either in person or online via Microsoft Teams, depending on the preference of the
 247 patient. Moreover, we will collect data on the usage behavior of patients when completing the
 248 questionnaires (i.e. time needed to complete questionnaires) and the amount of missing data. The focus
 249 groups with HCPs from participating practices will also be used to evaluate the understandability of the
 250 SDM-Q-Doc questionnaire.

251

252 **Table 1. Outcomes of the intended large-scale trial-based economic evaluation, including their**
 253 **measurement tools.**

Outcome	Measurement tool	Components
Patients		
Decisional Conflict	Decisional Conflict Scale (DCS) [32]	Patients will be asked to reflect on the treatment decision they made with their HCP and respond to 16 statements in the DCS using a five-point Likert scale (from completely agree to completely disagree).
Level of SDM	CollaboRATE survey [33, 34]	3 statements that assess patients' perception of being informed and engaged in decision-making steps on a scale of zero (no effort was made) to nine (every effort was made)
	SDM-Q-9 questionnaire [35]	The questionnaire contains nine statements each describing a different step of the SDM process. All items are scored on a six-point Likert scale from zero

(completely disagree) to five (completely agree). The questionnaire also includes two open-ended questions on what health problem was the subject of the consultation and which decision was made.

Patient knowledge	9 tailor-made multiple-choice questions	Assessing patients' understanding of the (risks and benefits of) glucose-lowering treatments.
Medication adherence	Medication Adherence Report Scale (MARS) [40] Prescription data	Assessing intentional and unintentional non-adherence (self-reported). Patients are asked to rate the frequency of events (i.e. forgetting a dose, changing a dose) on a five-point Likert Scale (ranging from never to always). Patients' pharmacy records for all T2DM medication will be collected.
Glycemic control	Primary care data	Glycemic control is assessed by obtaining HbA1c data from the primary care practice.
Costs (resource use)	An adapted version of the iMCQ and iPCQ questionnaire [37, 38]	The adapted version of the iMTA Productivity Costs Questionnaire (iPCQ) and the iMTA Medical Consumption Questionnaire (iMCQ) aims to measure relevant (non-)healthcare use as well as costs important to patients and families.
Health-related quality of life	Dutch EuroQol (EQ) 5D-5L (quality of life) [39]	The EQ 5D-5L assesses quality of life and includes the EQ-5D dimension and the EQ visual analog scale (VAS). EQ-5D comprises five dimensions: mobility, self-care, usual activities, pain, and anxiety. Each dimension of the EQ-5D is scored on a five-point Likert score (from no problems to extreme problems). The EQ

VAS is used to assess the patient's self-reported health on a visual analog scale.

Healthcare professionals

Level of SDM	SDM-Q-Doc questionnaire [35]	SDM-Q-9 questionnaire adapted to the HCP viewpoint to assess the extent of SDM during a consultation from the HCP perspective.
--------------	------------------------------	--

254 HCP: healthcare professional; SDM: shared decision-making.

255 Data collection and timeline

256 Patients from the intervention practices are requested to complete the questionnaires via the
257 online PatientPlus platform and patients from the control practices will complete questionnaires via
258 Qualtrics [41]. They will receive automatic notifications (via mail) prompting them to complete the
259 follow-up questionnaires at 3 and 9 months follow-up. Additionally, automated reminders will be sent
260 if the patient has not yet completed the questionnaire. HCPs from the control and intervention practices
261 will complete the questionnaire via Qualtrics [41]. The schedule of study enrolment and assessment can
262 be found in Table 2. Baseline measurements will capture sociodemographic and clinical patient
263 characteristics, patient knowledge, medication adherence, costs, and health-related quality of life. In
264 both study arms, patients complete the DCS, CollaboRATE survey, and SDM-Q-9 questionnaire directly
265 following the clinical encounter where a treatment decision is made. At the same time, HCPs complete
266 the SDM-Q-Doc questionnaire. Follow-ups at 3 months and 9 months will facilitate the measurement
267 of medication adherence, costs, and health-related quality of life. Semi-structured interviews with
268 patients will be held within 1 month after study participation and the focus groups with HCPs from
269 participating practices will be held at the end of the 9 months of implementation. Upon completion of
270 data collection at 9-month follow-up, we will gather information on the glycemetic control (at baseline,
271 and 3- and 9-month follow-up) of participating patients by obtaining their HbA1c values through their
272 primary care practice.

273

274 **Table 2. Schedule of study enrolment and assessment.**

		Enrolment			
Time point		t0	t1	t2	t3
Enrolment	Eligibility	x			
	Informed consent	x			
Assessment	Sociodemographic and clinical characteristics	x			
	Decisional Conflict		x	x	x
	Patient-rated level of SDM		x	x	x
	HCP-level of SDM		x	x	x
	Patient knowledge	x			
	Medication adherence	x		x	x
	Glycemic control	x		x	x
	Costs (resource use)	x		x	x
	Health-related quality of life	x		x	x
	Semi-structured interviews with patients		x		
	Focus group with HCPs				x

275 t0 = baseline measurement; t1 = directly following the clinical encounter where a treatment decision is
 276 made; t2 = 3-month follow-up; t3 = 9-month follow-up. SDM: shared decision-making, HCP: healthcare
 277 professional.

278

279 **Data analysis**

280 Descriptive analysis, i.e. counts and percentages for non-continuous data and mean scores and
 281 standard deviations for continuous data, will be reported for all variables. This includes
 282 sociodemographic and clinical characteristics, outcomes of the future economic evaluation, and
 283 estimates related to feasibility (e.g. recruitment rates and time to complete questionnaires). Moreover,
 284 we will analyze the missing data by identifying the amount of missing data and complementing this
 285 information with the results of the qualitative analysis. Descriptive analysis will be performed in Rstudio

286 [42]. Due to the nature of the pilot study, no statistical tests on the primary and secondary outcomes will
287 be conducted.

288 Interviews and focus groups will be audio-recorded and transcribed ad verbatim, and analyzed
289 in ATLAS.ti using thematic analysis with an inductive approach following three steps [43, 44]. First,
290 the transcripts will be read and re-read in a process called ‘familiarization’. Second, phrases, sentences,
291 and paragraphs with meaningful topics will be isolated and labeled by a code for each interview
292 transcript (independently by two researchers). Third, themes are developed by clustering codes with
293 similar meanings or interrelations, to understand, interpret, and report the main insights flowing from
294 the data. Analysis of the interviews and focus groups will be used to improve the questionnaires (e.g.
295 formulation of questions and possible adaptation to the cost questionnaire), recruitment strategies, and
296 study procedures.

297 The data management process (i.e. data collection, data processing, data quality, and data
298 analysis) and possible improvements thereof will be discussed with the research team in three 2-hour
299 meetings throughout the study period.

300

301 **Ethical considerations and declarations**

302 The Medical Ethics Review Committee of the academic hospital of Maastricht (azM) and
303 Maastricht University confirmed that the Medical Research Involving Human Subjects Act does not
304 apply to the pilot study and that official approval is not required (METC2023-0114). Patients will be
305 enrolled in the study after receiving face-to-face and written information about the research and after
306 giving written informed consent. Participants’ data will be used and retained by the researchers of
307 Maastricht University in compliance with the EU General Data Protection Regulation. Some of the data
308 will be collected via PatientPlus. PatientPlus has an information security management system that is
309 ISO27001 and NEN7510 certified. Researchers will be provided with an account for PatientPlus to
310 access the research data of patients. PatientPlus has only access to the anonymized data. The collected
311 data will be stored on the secure server of Maastricht University. All participants in this study will be
312 given an ID number to ensure the confidentiality of the patients and HCPs. Data in reports and

313 publications of this pilot study will not be traceable to the research participants. Research participants
314 have the right to withdraw from the research and withdraw their consent to the use of personal data at
315 any time during the study.

316

317 **Discussion**

318 This protocol outlines the approach for pilot testing our multistage SDM program in primary
319 care. Our primary objective is to address uncertainties around the feasibility of study methods, focusing
320 on aspects such as sample recruitment and retention, study management, and the feasibility of outcome
321 and cost measurements. Given that T2DM affects a large and diverse group of patients, it is important
322 to ensure that the study participants accurately represent this diversity, as it is essential for our intended
323 trial-based economic evaluation [14]. Previous randomized controlled trials researching the effects of
324 PDAs for T2DM experienced recruitment challenges [8-11]. These trials reported difficulties in
325 recruiting sufficient participants, timely recruitment, and inadvertent recruitment bias. Moreover, some
326 trials were unable to include a representative sample of patients with T2DM [9, 11]. It is also important
327 to acknowledge that the PDA has a digital format and questionnaires need to be completed digitally.
328 This may pose a limitation for individuals with low digital literacy, especially among older adults [45-
329 47]. We will therefore place a strong emphasis on the feasibility of the study processes in terms of
330 recruitment, retention, and consent rates within the pilot study. This will improve our understanding of
331 strategies to include a representative and diverse group of participants and we can apply these insights
332 to the recruitment process of the intended trial-based economic evaluation.

333 HCPs in primary care practices are faced with a high workload, time constraints, and stress
334 which are also identified as barriers to research participation [15, 16, 48]. To avoid willingness and
335 capacity problems of the participating practices related to the study, it is important to limit time expenses
336 and paperwork, and to provide adequate information and support. Therefore, as part of the pilot study,
337 we focus on how we can support general practices in effectively managing the challenges associated
338 with study participation. These insights will be instrumental in ensuring the successful implementation
339 of the multistage program into routine practice while minimizing the additional burden on practices.

340 There are valid and reliable instruments available (except for the cost questionnaire) for the
341 primary and secondary outcomes of the intended trial-based economic evaluation [32-35, 39, 40]. The
342 measurement process can be complex since outcomes are collected using different methods, from
343 different sources, and at various time points. It is important to avoid data management problems and
344 ensure successful data triangulation in the large-scale study. Hence, the primary and secondary outcomes
345 will be measured and analyzed during the small-scale pilot study. In the pilot study, we also focus on
346 the understandability and accessibility of the measurement tools and possible improvements thereof.
347 This is especially important since approximately 24.5% of the Dutch population experience low health
348 literacy and may therefore face difficulties when completing questionnaires [49]. Overall, the insights
349 gained from the pilot study will guide the refinement of the study procedures and intervention
350 components for the intended trial-based economic evaluation.

351 Our pilot study will contribute to the existing knowledge of effectively implementing PDAs into
352 clinical practice. Previous research showed that only 44% of existing PDAs for different conditions are
353 effectively integrated into clinical practice following their trial [46]. The intended trial-based economic
354 evaluation strengthens the limited evidence about the impact of person-centered care and SDM on mid
355 and long-term outcomes such as treatment adherence, health outcomes, and societal costs. It will
356 contribute to gaining a more comprehensive understanding of the potential benefits and challenges of
357 integrating person-centered SDM interventions into practice. Addressing these knowledge gaps is
358 essential to convince HCPs, policymakers, and payers to invest in the widespread implementation of
359 effective SDM support for person-centered care.

360

361 **Dissemination plan**

362 The results of this pilot study will be disseminated by means of conference presentations and
363 international peer-reviewed scientific journals. Moreover, attention will be given to promoting the
364 multistage SDM program among patients with T2DM and healthcare professionals within primary care.
365 This will help the future recruitment of patients with T2DM and primary care practices for the intended
366 trial-based economic evaluation. Our collaboration with the steering group consisting of patients with

367 T2DM, healthcare professionals, and patient organizations, established at the beginning of the
368 development of the multistage SDM program, will be continued for this pilot study. The steering group
369 and our collaboration with care group ‘Huisarts & Zorg’ and PatientPlus add valuable expertise and
370 experience from practice and policy as future end-users of our multistage SDM program. This
371 collaboration will help improve the implementation and dissemination of the program.
372

373 **References**

- 374 1. International Diabetes Federation. IDF Diabetes Atlas. Brussels, Belgium: 2021. Available at:
375 <https://www.diabetesatlas.org>.
- 376 2. American Diabetes Association Professional Practice C. 9. Pharmacologic Approaches to
377 Glycemic Treatment: Standards of Care in Diabetes—2024. *Diabetes Care*.
378 2023;47(Supplement_1):S158-S78. doi: 10.2337/dc24-S009.
- 379 3. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of
380 Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes
381 Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes*
382 *Care*. 2022;45(11):2753-86. doi: 10.2337/dci22-0034.
- 383 4. Nederlands Huisartsen Genootschap. NHG-standaard Diabetes mellitus type 2 (versie 5.6).
384 2023.
- 385 5. Tichler A, Hertroijs D, Ruwaard D, Brouwers M, Elissen A. Development of a patient decision
386 aid for type 2 diabetes mellitus: a patient-centered approach. *Research Square [Preprint]* [posted
387 2023 Oct 10; cited 2023 Oct 11]. 2023. Epub 10 October 2023. doi:
388 <https://doi.org/10.21203/rs.3.rs-3395717/v1>.
- 389 6. Stacey D, Legare F, Col NF, Bennett CL, Barry MJ, Eden KB, et al. Decision aids for people
390 facing health treatment or screening decisions. *Cochrane Database Syst Rev*.
391 2014;(1):CD001431. Epub 2014/01/28. doi: 10.1002/14651858.CD001431.pub4. PubMed
392 PMID: 24470076.
- 393 7. Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, et al. A new framework
394 for developing and evaluating complex interventions: update of Medical Research Council
395 guidance. *BMJ*. 2021;374:n2061. doi: 10.1136/bmj.n2061.
- 396 8. Branda ME, LeBlanc A, Shah ND, Tiedje K, Ruud K, Van Houten H, et al. Shared decision
397 making for patients with type 2 diabetes: a randomized trial in primary care. *BMC Health Serv*
398 *Res*. 2013;13:301-. doi: 10.1186/1472-6963-13-301. PubMed PMID: 23927490.

- 399 9. Kellar I, Mann E, Kinmonth AL, Prevost AT, Sutton S, Marteau TM. Can informed choice
400 invitations lead to inequities in intentions to make lifestyle changes among participants in a
401 primary care diabetes screening programme? Evidence from a randomized trial. *Public Health*.
402 2011;125(9):645-52. doi: <https://doi.org/10.1016/j.puhe.2011.05.010>.
- 403 10. Mathers N, Ng CJ, Campbell MJ, Colwell B, Brown I, Bradley A. Clinical effectiveness of a
404 patient decision aid to improve decision quality and glycaemic control in people with diabetes
405 making treatment choices: a cluster randomised controlled trial (PANDAs) in general practice.
406 *BMJ Open*. 2012;2(6):e001469. doi: [10.1136/bmjopen-2012-001469](https://doi.org/10.1136/bmjopen-2012-001469).
- 407 11. Mullan RJ, Montori VM, Shah ND, Christianson TJH, Bryant SC, Guyatt GH, et al. The
408 Diabetes Mellitus Medication Choice Decision Aid: A Randomized Trial. *Arch Intern Med*.
409 2009;169(17):1560-8. doi: [10.1001/archinternmed.2009.293](https://doi.org/10.1001/archinternmed.2009.293).
- 410 12. Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP, et al. A tutorial on pilot studies: the
411 what, why and how. *BMC Med Res Methodol*. 2010;10(1):1. doi: [10.1186/1471-2288-10-1](https://doi.org/10.1186/1471-2288-10-1).
- 412 13. Van Teijlingen E, Hundley V. The importance of pilot studies. *Social research update*.
413 2001;(35):1-4.
- 414 14. Black SA. Diabetes, diversity, and disparity: what do we do with the evidence? *Am J Public*
415 *Health*. 2002;92(4):543-8. doi: [10.2105/ajph.92.4.543](https://doi.org/10.2105/ajph.92.4.543). PubMed PMID: 11919048; PubMed
416 Central PMCID: PMCPMC1447113.
- 417 15. McKinley N, McCain RS, Convie L, Clarke M, Dempster M, Campbell WJ, Kirk SJ. Resilience,
418 burnout and coping mechanisms in UK doctors: a cross-sectional study. *BMJ Open*.
419 2020;10(1):e031765. Epub 20200127. doi: [10.1136/bmjopen-2019-031765](https://doi.org/10.1136/bmjopen-2019-031765). PubMed PMID:
420 31988223; PubMed Central PMCID: PMCPMC7045750.
- 421 16. West CP, Dyrbye LN, Shanafelt TD. Physician burnout: contributors, consequences and
422 solutions. *J Intern Med*. 2018;283(6):516-29. Epub 20180324. doi: [10.1111/joim.12752](https://doi.org/10.1111/joim.12752).
423 PubMed PMID: 29505159.
- 424 17. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT
425 2010 statement: extension to randomised pilot and feasibility trials. *Pilot and Feasibility Studies*.
426 2016;2(1):64. doi: [10.1186/s40814-016-0105-8](https://doi.org/10.1186/s40814-016-0105-8).

- 427 18. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT
428 2013 Statement: Defining Standard Protocol Items for Clinical Trials. *Ann Intern Med.*
429 2013;158(3):200-7. doi: 10.7326/0003-4819-158-3-201302050-00583.
- 430 19. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013
431 explanation and elaboration: guidance for protocols of clinical trials. *BMJ : British Medical*
432 *Journal.* 2013;346:e7586. doi: 10.1136/bmj.e7586.
- 433 20. Thabane L, Lancaster G. A guide to the reporting of protocols of pilot and feasibility trials. *Pilot*
434 *and Feasibility Studies.* 2019;5(1):37. doi: 10.1186/s40814-019-0423-8.
- 435 21. Nederland Z. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg
436 (versie 2024). 2024. p. 38.
- 437 22. Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al.
438 Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022)
439 Statement: Updated Reporting Guidance for Health Economic Evaluations. *Value Health.*
440 2022;25(1):3-9. doi: <https://doi.org/10.1016/j.jval.2021.11.1351>.
- 441 23. InEen. Benchmark Transparante Ketenzorg 2022. Rapportage zorgprogramma's diabetes
442 mellitus type 2, COPD, Astma en Vasculair Risico Management bij patiënten met een
443 hartvaatziekte en een verhoogd risico op hartvaatziekten 2023.
- 444 24. Struijs JN, van Til JT, Baan CA. Experimenteren met de keten-dbc diabetes. Bilthoven: RIVM,
445 2009.
- 446 25. Nederlands Huisartsen Genootschap (NHG). Behandeling bij diabetes type 2 2022. Available
447 from: [https://www.thuisarts.nl/diabetes-type-2/ik-heb-diabetes-type-2#behandeling-bij-](https://www.thuisarts.nl/diabetes-type-2/ik-heb-diabetes-type-2#behandeling-bij-diabetes-type-2)
448 [diabetes-type-2.](https://www.thuisarts.nl/diabetes-type-2/ik-heb-diabetes-type-2#behandeling-bij-diabetes-type-2)
- 449 26. Fayers PM, Jordhù MS, Kaasa S. Cluster-randomized trials. *Palliat Med.* 2002;16(1):69-70.
450 doi: 10.1191/0269216302pm503xx.
- 451 27. Kang M, Ragan BG, Park JH. Issues in outcomes research: an overview of randomization
452 techniques for clinical trials. *J Athl Train.* 2008;43(2):215-21. Epub 2008/03/18. doi:
453 10.4085/1062-6050-43.2.215. PubMed PMID: 18345348; PubMed Central PMCID:
454 PMCPMC2267325.

- 455 28. Elwyn G, O'Connor A, Stacey D, Volk R, Edwards A, Coulter A, et al. Developing a quality
456 criteria framework for patient decision aids: online international Delphi consensus process. *BMJ*
457 (Clinical research ed). 2006;333(7565):417-. Epub 2006/08/14. doi:
458 10.1136/bmj.38926.629329.AE. PubMed PMID: 16908462.
- 459 29. Elwyn G, O'Connor AM, Bennett C, Newcombe RG, Politi M, Durand MA, et al. Assessing the
460 quality of decision support technologies using the International Patient Decision Aid Standards
461 instrument (IPDASi). *PLoS One*. 2009;4(3):e4705. Epub 2009/03/05. doi:
462 10.1371/journal.pone.0004705. PubMed PMID: 19259269; PubMed Central PMCID:
463 PMCPMC2649534.
- 464 30. Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot
465 randomised trial to minimise the overall trial sample size for the external pilot and main trial for
466 a continuous outcome variable. *Stat Methods Med Res*. 2016;25(3):1057-73. Epub 2015/06/21.
467 doi: 10.1177/0962280215588241. PubMed PMID: 26092476; PubMed Central PMCID:
468 PMCPMC4876429.
- 469 31. Yu CH, Ivers NM, Stacey D, Rezmovitz J, Telner D, Thorpe K, et al. Impact of an
470 interprofessional shared decision-making and goal-setting decision aid for patients with diabetes
471 on decisional conflict – study protocol for a randomized controlled trial. *Trials*. 2015;16(1):286.
472 doi: 10.1186/s13063-015-0797-8.
- 473 32. O'Connor AM. Validation of a Decisional Conflict Scale. *Med Decis Making*. 1995;15(1):25-
474 30. doi: 10.1177/0272989X9501500105.
- 475 33. Barr PJ, Thompson R, Walsh T, Grande SW, Ozanne EM, Elwyn G. The psychometric
476 properties of CollaboRATE: a fast and frugal patient-reported measure of the shared decision-
477 making process. *J Med Internet Res*. 2014;16(1):e2-e. doi: 10.2196/jmir.3085. PubMed PMID:
478 24389354.
- 479 34. Elwyn G, Barr PJ, Grande SW, Thompson R, Walsh T, Ozanne EM. Developing CollaboRATE:
480 a fast and frugal patient-reported measure of shared decision making in clinical encounters.
481 *Patient Educ Couns*. 2013;93(1):102-7. Epub 2013/06/19. doi: 10.1016/j.pec.2013.05.009.
482 PubMed PMID: 23768763.

- 483 35. Rodenburg-Vandenbussche S, Pieterse AH, Kroonenberg PM, Scholl I, van der Weijden T,
484 Luyten GP, et al. Dutch Translation and Psychometric Testing of the 9-Item Shared Decision
485 Making Questionnaire (SDM-Q-9) and Shared Decision Making Questionnaire-Physician
486 Version (SDM-Q-Doc) in Primary and Secondary Care. PLoS One. 2015;10(7):e0132158. Epub
487 2015/07/08. doi: 10.1371/journal.pone.0132158. PubMed PMID: 26151946; PubMed Central
488 PMCID: PMC4494856.
- 489 36. Fox-Rushby J. CJ. Economic Evaluation. London: Oxford University Press; 2006.
- 490 37. www.imta.nl (iMTA Productivity and Health Research Group. Handleiding iMTA Medical Cost
491 Questionnaire (*iMCQ*) Rotterdam: iMTA, Erasmus Universiteit Rotterdam, 2018)
- 492 38. www.imta.nl (iMTA Productivity and Health Research Group. Handleiding iMTA Productivity
493 Cost Questionnaire (*iPCQ*). Rotterdam: iMTA, Erasmus Universiteit, 2018)
- 494 39. EuroQol. EuroQol 2017. Available from: [https://euroqol.org/eq-5d-instruments/eq-5d-3l-](https://euroqol.org/eq-5d-instruments/eq-5d-3l-about/)
495 [about/](https://euroqol.org/eq-5d-instruments/eq-5d-3l-about/).
- 496 40. Chan AHY, Horne R, Hankins M, Chisari C. The Medication Adherence Report Scale: A
497 measurement tool for eliciting patients' reports of nonadherence. Br J Clin Pharmacol.
498 2020;86(7):1281-8. Epub 20200518. doi: 10.1111/bcp.14193. PubMed PMID: 31823381;
499 PubMed Central PMCID: PMC7319010.
- 500 41. Qualtrics. Provo, Utah, USA, 2005. Available from: <https://www.qualtrics.com/>.
- 501 42. Team R. RStudio: Integrated Development for R. 1.4.1106 ed. Boston, MA: RStudio, PBC;
502 2020.
- 503 43. ATLAS.ti Scientific Software Development GmbH. ATLAS.ti Scientific Software
504 Development GmbH.
- 505 44. Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Research in Psychology.
506 2006;3(2):77-101. doi: 10.1191/1478088706qp063oa.
- 507 45. Hargittai E, Piper AM, Morris MR. From internet access to internet skills: digital inequality
508 among older adults. Universal Access in the Information Society. 2019;18(4):881-90. doi:
509 10.1007/s10209-018-0617-5.

- 510 46. Stacey D, Suwalska V, Boland L, Lewis KB, Pesseau J, Thomson R. Are Patient Decision Aids
511 Used in Clinical Practice after Rigorous Evaluation? A Survey of Trial Authors. *Med Decis*
512 *Making*. 2019;39(7):805-15. Epub 2019/08/20. doi: 10.1177/0272989x19868193. PubMed
513 PMID: 31423911.
- 514 47. van Deursen AJ, van Dijk JA. The first-level digital divide shifts from inequalities in physical
515 access to inequalities in material access. *New Media Soc*. 2019;21(2):354-75. Epub 2019/03/20.
516 doi: 10.1177/1461444818797082. PubMed PMID: 30886536; PubMed Central PMCID:
517 PMC6380454.
- 518 48. Brodaty H, Gibson LH, Waine ML, Shell AM, Lilian R, Pond CD. Research in general practice:
519 a survey of incentives and disincentives for research participation. *Ment Health Fam Med*.
520 2013;10(3):163-73. PubMed PMID: 24427184; PubMed Central PMCID: PMC3822664.
- 521 49. Willems AEM, Heijmans M, Brabers AEM, Rademakers J. Gezondheidsvaardigheden in
522 Nederland: factsheet cijfers 2021. Utrecht: Nivel. 2022.

523 **Supporting information**

524 **S1 File. SPIRIT checklist.**

525 **S2 File. CONSORT checklist.**

526 **S3. File. Protocol**




Figure 1